Abstract: For each of a number of users (11, 12, 13), a network-based server (14) maintains a respective data set (141, 142, 143) of each data file currently stored on the user device, such as scheduling details, electronic mail, documents, etc. Each data set comprises a master copy (161) indicative of the latest data intended for that user (11). When a user (either the user associated with the user device, or some other user (151, 152, 153) authorised to do so) makes a change to the user data, for example rescheduling a meeting, the master copy (161) is updated. The server (14) also identifies how this data differs from that held on a second copy (171), which duplicates what is currently stored on the terminal, and generates a third dataset (181) identifying the changes that would need to be made to change the duplicate copy (171) to correspond to the master copy (161). This change data is forwarded to the user terminal when it next makes contact with the network.

Abstract: The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.

Abstract: A telecommunications network termination device has the capability to connect to a network access point using a primary fixed line address by a first route and also, using a second network address, by a backup routing to a shared wireless access point. Connection status messages are transmitted over the primary routing. If these are not detected by the network, it causes traffic to the user device to be diverted over the backup routing to the second network address. It also transmits instructions to the user device to route outgoing traffic by the same secondary route. The secondary route is identified from network tolopogy data stored by the network control server.

Abstract: A mobile communications handset (12) is capable of connection through two different networks (2, 27). When it is out of contact with its preferred local wireless access system (27), the handset will seek a hand-over to the cellular network (2), and will become registered as a “roaming” handset currently connected to the cellular network (2). The cellular network (2) reports this location information to the call server (28), as it would to the HLR of any normal visiting handset, so that incoming calls to the PSTN (6) destined for the user (12) can be routed by way of the cellular network. Outgoing calls are handled as conventional cellular telephony calls. When contact with a local wireless access system (27) is re-established, the contact information is passed to the call server 28, which reports to the cellular network (2) that a handover has occurred.

Abstract: A mobile handset is capable of establishing communication through a cellular network (2) and a local access system (7, 8, 27), which has an interface (9) with the cellular network to allow the handset's presence to be logged by the switching centre of the cellular system (2). If the handset requires a handover between local access systems (7, 27), this is provided for by a handover processor (97) in the interface (9), instead of in the mobile switching centre (2). This allows the connection between the mobile access bridge (9) and the mobile switching centre (2) to remain unchanged, and sessions are still routed by the mobile switching centre (2) to the mobile access bridge (9), which emulates a base site controller.

Abstract: If an attempt by a first user (3) to contact another party (6) fails, a callback server (1) sets a flag (246). The callback server (1) monitors terminals that have such flags set (25) and is arranged to transmit an alert (27) to the calling party (3) when the called party (6) next becomes available. However, if at the time when the called party (6) becomes available, the calling party (3) is himself no longer available, being now switched off or busy, an additional flag (243) in the store (2), indicative of activity by the calling party (3), prevents a callback alert from being generated until the monitoring process (25) can obtain availability indications (263, 266) in respect of both parties (3, 69) simultaneously. Availability may be determined by factors such as available bandwidth or terminal capabilities. A callback may be initiated when a predetermined number of called parties become available to participate in a conference call.

Abstract: Methods of inducing the expression of a Smad in a cell or tissue comprising the step of contacting the cell or tissue capable of expressing the Smad with a bone morphogenic protein are provided. Methods of inducing tissue formation and repairing a tissue defect or regenerating tissue, at a target locus in a mammal comprising the step of administering to the target locus a Smad are also provided.

Abstract: The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided.

Abstract: The present invention relates generally to methods and compositions for identifying morphogenic protein analogs. In one embodiment, this invention relates to an osteogenic protein reponsive transcription inhibitory element. This invention also relates to the identified morphogenic protein analogs which can mimic the biological effects of morphogenic proteins, particularly those relating to the BMP family such as osteogenic protein (OP-1), on the regulation of gene expression and tissue inductive capabilities.

Abstract: This invention features devices and methods for inducing tissue formation in a mammal, involving the use of a morphogenic protein, a hormone and a soluble receptor of the hormone. The hormone and receptor thereof are used to enhance the tissue inductive activity of the morphogenic protein.

Abstract: This invention features devices and methods for inducing tissue formation in a mammal, involving the use of a morphogenic protein, a hormone and a soluble receptor of the hormone. The hormone and receptor thereof are used to enhance the tissue inductive activity of the morphogenic protein.

Abstract: Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

Abstract: Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

Abstract: Novel 1, 4, 5- substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.

Abstract: The present invention relates generally to methods and compositions for identifying morphogenic protein analogs. In one embodiment, this invention relates to an osteogenic protein reponsive transcription inhibitory element. This invention also relates to the identified morphogenic protein analogs which can mimic the biological effects of morphogenic proteins, particularly those relating to the BMP family such as osteogenic protein (OP-1), on the regulation of gene expression and tissue inductive capabilities.

Abstract: The present invention relates generally to methods and compositions for identifying morphogenic protein analogs. In one embodiment, this invention relates to an osteogenic protein reponsive transcription inhibitory element. This invention also relates to the identified morphogenic protein analogs which can mimic the biological effects of morphogenic proteins, particularly those relating to the BMP family such as osteogenic protein (OP-1), on the regulation of gene expression and tissue inductive capabilities.

Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.

Abstract: Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

Abstract: Novel 1, 4, 5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.